zurück

Pembrolizumab (new indication: endometrial carcinoma, after platinum-based therapy, in combination with lenvatinib)

Subject:

  • Active Substance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Endometrial carcinoma
  • Pharmaceutical company: MSD Sharp & Dohme GmbH

Time table:

  • Start: 15.01.2022
  • Final decision by G-BA: 07.07.2022

Final decision:

  • Indication for a considerable additional benefit